Zhejiang Xianju Pharmaceutical Co.,Ltd. (SHE: 002332)

Zhejiang Xianju Pharmaceutical Co.,Ltd. Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	1,299	1,660	1,720	1,267	1,438	1,028
Short-Term Investments	-	-	-	-	-	21.98
Trading Asset Securities	-	-	-	500.64	500.44	-
Cash & Short-Term Investments	1,299	1,660	1,720	1,768	1,938	1,050
Cash Growth	-25.14%	-3.51%	-2.67%	-8.80%	84.59%	17.64%
Accounts Receivable	873.92	726.38	706.37	752.24	929.85	994.53
Other Receivables	54.02	15.41	70.84	17.66	18.19	2.96
Receivables	927.94	741.79	777.21	769.9	948.05	997.49
Inventory	894.87	922.88	890.5	910.7	725.66	671.83
Other Current Assets	77.08	75.16	46.11	127.64	137.01	137.29
Total Current Assets	3,199	3,400	3,434	3,576	3,749	2,857
Property, Plant & Equipment	2,446	2,257	2,038	1,997	1,925	1,880
Long-Term Investments	315.77	280.92	278.26	280.21	281.93	198.23
Goodwill	604.45	606.96	573.27	557.57	619.77	603.59
Other Intangible Assets	157.01	166.49	177.18	178.4	184	197.02
Long-Term Deferred Tax Assets	27.2	21.62	28.61	25.39	27.26	30.97
Long-Term Deferred Charges	11.64	10.16	10.19	12.55	15.83	17.54
Other Long-Term Assets	146.6	249.99	197.84	101.12	35.25	40.75
Total Assets	6,908	6,993	6,738	6,728	6,838	5,824
Accounts Payable	289.55	484.51	354.78	385.31	417.72	362.38
Accrued Expenses	65.76	127.86	124.54	175.4	165.61	144.67
Short-Term Debt	5.02	1.03	37.4	65.59	310.77	535.3
Current Portion of Long-Term Debt	58.84	166.36	102.4	346.8	293.07	276.37
Current Portion of Leases	-	3.47	6.37	6.22	-	-
Current Income Taxes Payable	73.08	11	28.43	21.94	42.35	35.67
Current Unearned Revenue	33.75	31.33	46.89	41.9	16.12	27.37
Other Current Liabilities	211.7	221.36	268.26	346.94	373.18	365.46
Total Current Liabilities	737.71	1,047	969.07	1,390	1,619	1,747
Long-Term Debt	37.38	38.74	193.85	313.14	574.45	960.06
Long-Term Leases	3.81	9.75	4.4	7.49	-	-
Long-Term Unearned Revenue	51	57.86	54.53	59.28	53.84	51.09
Long-Term Deferred Tax Liabilities	-	-	0.23	-	-	-
Other Long-Term Liabilities	9.26	9.53	8.49	8.31	8.75	7.39
Total Liabilities	839.16	1,163	1,231	1,778	2,256	2,766
Common Stock	989.2	989.2	989.2	989.2	989.2	916.21
Additional Paid-In Capital	1,820	1,820	1,803	1,802	1,801	851.9
Retained Earnings	3,160	2,926	2,660	2,059	1,586	1,173
Comprehensive Income & Other	45.22	50.61	5.74	-15.98	68.46	0.23
Total Common Equity	6,014	5,786	5,457	4,834	4,445	2,942
Minority Interest	54.44	43.92	50.01	115.66	137.42	117.08
Shareholders' Equity	6,069	5,830	5,507	4,950	4,582	3,059
Total Liabilities & Equity	6,908	6,993	6,738	6,728	6,838	5,824
Total Debt	105.05	219.36	344.42	739.25	1,178	1,772
Net Cash (Debt)	1,194	1,441	1,376	1,028	759.77	-721.8
Net Cash Growth	-18.79%	4.70%	33.81%	35.35%	-	-
Net Cash Per Share	1.21	1.46	1.39	1.04	0.83	-0.79
Filing Date Shares Outstanding	989.2	989.2	989.2	989.2	989.2	916.21
Total Common Shares Outstanding	989.2	989.2	989.2	989.2	989.2	916.21
Working Capital	2,461	2,353	2,465	2,186	2,130	1,109
Book Value Per Share	6.08	5.85	5.52	4.89	4.49	3.21
Tangible Book Value	5,253	5,013	4,707	4,098	3,641	2,141
Tangible Book Value Per Share	5.31	5.07	4.76	4.14	3.68	2.34
Buildings	-	1,112	977.17	1,025	1,026	986.56
Machinery	-	291.83	275.36	1,506	1,443	1,355
Construction In Progress	-	522.17	374.2	367.9	250.42	429.23

Source: S&P Capital IQ. Standard template. Financial Sources.